<DOC>
	<DOCNO>NCT00111241</DOCNO>
	<brief_summary>Many woman breast cancer treat class drug call aromatase inhibitor ( mainly letrozole anastrozole ) , lower amount estrogen produce body . Women aromatase inhibitor appear experience joint pain arthralgia . The aim study determine whether joint pain experience woman aromatase inhibitor associate defect cartilage , compare woman receive therapy . Using magnetic resonance imaging ( MRI ) technique , knee joint examine ass change cartilage volume time .</brief_summary>
	<brief_title>Changes Knee Articular Cartilage Volume Women Aromatase Inhibitors</brief_title>
	<detailed_description>The mechanism increase bone loss fracture risk clearly related depletion estrogen production bone . But high rate reporting arthralgia , fracture joint pain amongst woman aromatase inhibitor understood . Using magnetic resonance imaging ( MRI ) measure knee articular cartilage volume , demonstrate post menopausal hormone therapy use least five year associate retention articular cartilage knee , indicate oestrogen may protect development osteoarthritis post menopausal woman . Furthermore , recently observe free testosterone associate loss tibial cartilage , take account age , body mass index , baseline tibial cartilage volume , tibial plateau area total bone mineral content healthy men . Whether excess testosterone oestrogen consequence aromatase inhibition adverse effect articular cartilage volume warrant investigation . This study include non-hysterectomised woman age 40 65 year undergone breast surgery commence aromatase inhibitor within precede 12 week . The control group ( fully recruit ) include non-hysterectomised , healthy woman age 40 65 year . A MRI dominant knee use compare change knee articular volume time . A MRI do baseline 2 year . Changes knee articular volume primary outcome . We also use opportunity compare menopausal symptom ( assess use Menopause Quality Life [ MENQOL ] questionnaire ) woman treat aromatase inhibitor . Well-being also assess use Psychological General Well-Being index .</detailed_description>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Group 1 : Aged 40 65 Nonhysterectomised woman undergone breast surgery Women aromatase inhibitor within precede 12 week Group 2 : control group Healthy , nonhysterectomised woman age 4065 . Previous knee injury require nonweight bearing treatment &gt; 24 hr surgery ( include arthroscopy ) Inability complete study ( eg propose relocation ) Contraindication undergo MRI include pacemaker , metal suture , presence shrapnel , iron filing eye Claustrophobia Additional Exclusions Group 1 Treatment tamoxifen &gt; 8 week prior commencement Knee pain last &gt; 24 hour last 5 year ( prior commencement anastrozole letrozole ) Anastrazole Letrozole therapy &gt; 12 week</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>bone fracture</keyword>
	<keyword>cartilage</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>knee articular cartilage volume</keyword>
</DOC>